Hanlim Pharm
Hanlim Pharm (한림제약) is a private South Korean pharmaceutical company founded in 1989, headquartered in Seocho, with 251-500 employees. Specific product lines, therapeutic focus, and financials are not publicly disclosed; recent activity includes a corporate venture investment into biotech Invion in December 2025.
- Company typePrivate
- Founded1989
- HeadquartersSeocho, South Korea
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hanlim Pharm does
Hanlim Pharm (한림제약) is a private South Korean pharmaceutical company founded in 1989, headquartered in Seocho, South Korea, with a workforce of 251-500 employees. The company operates in the Korean pharmaceutical sector; however, no specific therapeutic areas, product lines, manufacturing capabilities, distribution footprint, or target customer segments are disclosed in the available sources. The company's external-facing digital presence is minimal, with its website (hanlim.com/) containing only basic branding text and no detailed product or service description.
The company's business model mechanics — including pricing structures, go-to-market channels, prescription vs. OTC mix, and revenue composition — are not publicly disclosed. What is observable from the source data is a single corporate venture activity: on 2025-12-23, Hanlim Pharm provided non-dilutive funding to Invion, an Australian-listed pharmaceutical/biotech company, alongside the Korean government research fund. This transaction suggests Hanlim Pharm has discretionary capital and is pursuing external innovation exposure, possibly as a complement to any in-house R&D efforts, but the broader strategic intent is not evidenced in the sources.
The data set is notably thin across all standard PE/VC diligence dimensions: no management team is listed, no subsidiaries, no M&A history, no certifications or regulatory filings, no customer logos, and no technology stack. Investors and acquirers evaluating Hanlim Pharm would need to source primary information directly from the company to assess product portfolio, pipeline, regulatory approvals, distribution channels, and financial profile.
Hanlim Pharm firmographics
Firmographics- Name
- Hanlim Pharm
- Legal name
- 한림제약 (Hanlim Pharm)
- Website
- https://hanlim.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Hanlim Pharm (한림제약) is a private South Korean pharmaceutical company founded in 1989, headquartered in Seocho, with 251-500 employees. Specific product lines, therapeutic focus, and financials are not publicly disclosed; recent activity includes a corporate venture investment into biotech Invion in December 2025.
- Ownership category
- akta.pro rank
Where Hanlim Pharm is headquartered
LocationHeadquarters
- HQ city
- Seocho
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Hanlim Pharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Hanlim Pharm product offering
Product offeringCore offering
Hanlim Pharm is a South Korea-based pharmaceutical company. No specific products, therapeutic areas, manufacturing capabilities, or service offerings are described in the available source data. The only activity evidenced is the company's provision of non-dilutive funding to Invion alongside a Korean government research fund.
Product overview
No specific product or service offerings are described in the available source data for Hanlim Pharm. The sources contain only a news article about Invion securing non-dilutive funding from Hanlim Pharm and the Korean government research fund, and a minimal webpage displaying the company name in Korean (한림제약).
Differentiator
Problem solved
Functional benefit
Hanlim Pharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Hanlim Pharm partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
Hanlim Pharm competitors and assessment
Company assessmentDirect peers
- Daewoong Pharmaceutical: One of South Korea's largest established pharmaceutical manufacturers with branded and generic portfolios across multiple therapeutic areas. Highly comparable to Hanlim Pharm as another Korea-based, privately disciplined pharma with a domestic manufacturing base and 1980s-era origins.
- Hanmi Pharmaceutical: Korean pharmaceutical company developing branded and specialty medicines with a long operating history and aggressive licensing strategy. Comparable to Hanlim on geography, vintage, and finished-dose pharma business, though larger and more internationally active.
- Yuhan Corporation: Major Korean pharmaceutical manufacturer with a diversified branded, OTC, and chemical intermediates portfolio founded decades ago. Comparable to Hanlim Pharm as a long-standing Korea-headquartered finished-dose pharma operator.
- Dong-A ST: Korean pharmaceutical manufacturer with a strong domestic finished-dose and specialty franchise. Comparable as a similarly aged, Korea-based pharma with branded generics and specialty products aimed primarily at the domestic market.
- JW Pharmaceutical: Mid-sized Korean pharmaceutical firm focused on finished-dose generics, specialty pharma, and OTC products. Comparable to Hanlim Pharm on mid-market Korean pharma positioning and product mix orientation.
- Chong Kun Dang Pharmaceutical: Heritage Korean pharmaceutical manufacturer with branded generics and biosimilars, comparable in vintage and domestic-market focus to Hanlim Pharm.
- GC Pharma (Green Cross): Korean biopharmaceutical company with vaccines, plasma products, and specialty therapeutics. Comparable to Hanlim in domestic Korean pharma heritage and finished-dose operating model, with deeper biologics exposure.
- Dongkook Pharmaceutical: Mid-sized Korean pharmaceutical manufacturer producing finished-dose generics and selected specialty products. Closely analogous in scale and product orientation to Hanlim Pharm.
- Samjin Pharmaceutical: Korean mid-cap pharmaceutical company specializing in finished-dose generics and selected specialty therapeutics. Comparable to Hanlim Pharm as a similarly positioned domestic Korean pharmaceutical operator.
Broad incumbents
- Celltrion: South Korean biosimilar and biopharmaceutical leader with global commercialization. Comparable industry segment to Hanlim Pharm but substantially larger and focused on biologics rather than small-molecule finished-dose pharma.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Hanlim Pharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hanlim Pharm leadership team
Management profileNumber of profiles
Hanlim Pharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hanlim Pharm M&A and investment
M&A and investmentM&A
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hanlim Pharm
What does Hanlim Pharm do?
Hanlim Pharm is a South Korea-based pharmaceutical company. No specific products, therapeutic areas, manufacturing capabilities, or service offerings are described in the available source data. The only activity evidenced is the company's provision of non-dilutive funding to Invion alongside a Korean government research fund.
When was Hanlim Pharm founded?
Hanlim Pharm was founded in 1989. It employs 251 to 500 people.
Where is Hanlim Pharm based?
Hanlim Pharm is headquartered in Seocho, South Korea, in the Asia region.
Who are Hanlim Pharm's main competitors?
Direct peers on record are Daewoong Pharmaceutical, Hanmi Pharmaceutical, Yuhan Corporation, Dong-A ST, JW Pharmaceutical, Chong Kun Dang Pharmaceutical, GC Pharma (Green Cross), Dongkook Pharmaceutical and Samjin Pharmaceutical. Celltrion is listed as a broad incumbent.
Does Hanlim Pharm have an API?
No public API is recorded for Hanlim Pharm.